Literature DB >> 22051914

Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.

Laura Ferraiuolo1, Janine Kirby, Andrew J Grierson, Michael Sendtner, Pamela J Shaw.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a genetically diverse disease. At least 15 ALS-associated gene loci have so far been identified, and the causative gene is known in approximately 30% of familial ALS cases. Less is known about the factors underlying the sporadic form of the disease. The molecular mechanisms of motor neuron degeneration are best understood in the subtype of disease caused by mutations in superoxide dismutase 1, with a current consensus that motor neuron injury is caused by a complex interplay between multiple pathogenic processes. A key recent finding is that mutated TAR DNA-binding protein 43 is a major constituent of the ubiquitinated protein inclusions in ALS, providing a possible link between the genetic mutation and the cellular pathology. New insights have also indicated the importance of dysregulated glial cell-motor neuron crosstalk, and have highlighted the vulnerability of the distal axonal compartment early in the disease course. In addition, recent studies have suggested that disordered RNA processing is likely to represent a major contributing factor to motor neuron disease. Ongoing research on the cellular pathways highlighted in this Review is predicted to open the door to new therapeutic interventions to slow disease progression in ALS.

Entities:  

Mesh:

Year:  2011        PMID: 22051914     DOI: 10.1038/nrneurol.2011.152

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  194 in total

1.  VEGF protects spinal motor neurons against chronic excitotoxic degeneration in vivo by activation of PI3-K pathway and inhibition of p38MAPK.

Authors:  Luis B Tovar-Y-Romo; Ricardo Tapia
Journal:  J Neurochem       Date:  2010-12       Impact factor: 5.372

2.  Axonal mitochondrial transport and potential are correlated.

Authors:  Kyle E Miller; Michael P Sheetz
Journal:  J Cell Sci       Date:  2004-05-18       Impact factor: 5.285

3.  Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease.

Authors:  Agnes A Luty; John B J Kwok; Carol Dobson-Stone; Clement T Loy; Kirsten G Coupland; Helena Karlström; Tomasz Sobow; Joanna Tchorzewska; Aleksandra Maruszak; Maria Barcikowska; Peter K Panegyres; Cezary Zekanowski; William S Brooks; Kelly L Williams; Ian P Blair; Karen A Mather; Perminder S Sachdev; Glenda M Halliday; Peter R Schofield
Journal:  Ann Neurol       Date:  2010-11       Impact factor: 10.422

4.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

5.  TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97.

Authors:  Gillian P Ritson; Sara K Custer; Brian D Freibaum; Jake B Guinto; Dyanna Geffel; Jennifer Moore; Waixing Tang; Matthew J Winton; Manuela Neumann; John Q Trojanowski; Virginia M-Y Lee; Mark S Forman; J Paul Taylor
Journal:  J Neurosci       Date:  2010-06-02       Impact factor: 6.167

6.  RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS.

Authors:  Shangxi Xiao; Teresa Sanelli; Samar Dib; David Sheps; Joseph Findlater; Juan Bilbao; Julia Keith; Lorne Zinman; Ekaterina Rogaeva; Janice Robertson
Journal:  Mol Cell Neurosci       Date:  2011-03-21       Impact factor: 4.314

7.  ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study.

Authors:  Michael A van Es; Paul W Van Vught; Hylke M Blauw; Lude Franke; Christiaan G Saris; Peter M Andersen; Ludo Van Den Bosch; Sonja W de Jong; Ruben van 't Slot; Anna Birve; Robin Lemmens; Vianney de Jong; Frank Baas; Helenius J Schelhaas; Kristel Sleegers; Christine Van Broeckhoven; John H J Wokke; Cisca Wijmenga; Wim Robberecht; Jan H Veldink; Roel A Ophoff; Leonard H van den Berg
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

8.  Control of motoneuron survival by angiogenin.

Authors:  Dairín Kieran; Jordi Sebastia; Matthew J Greenway; Matthew A King; Dervla Connaughton; Caoimhin G Concannon; Beau Fenner; Orla Hardiman; Jochen H M Prehn
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

9.  A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice.

Authors:  Smita Saxena; Erik Cabuy; Pico Caroni
Journal:  Nat Neurosci       Date:  2009-03-29       Impact factor: 24.884

10.  Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Authors:  Richard J Mead; Ellen J Bennett; Aneurin J Kennerley; Paul Sharp; Claire Sunyach; Paul Kasher; Jason Berwick; Brigitte Pettmann; Guiseppe Battaglia; Mimoun Azzouz; Andrew Grierson; Pamela J Shaw
Journal:  PLoS One       Date:  2011-08-18       Impact factor: 3.240

View more
  237 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

Review 2.  Toward precision medicine in amyotrophic lateral sclerosis.

Authors:  Zhang-Yu Zou; Chang-Yun Liu; Chun-Hui Che; Hua-Pin Huang
Journal:  Ann Transl Med       Date:  2016-01

3.  ALS-linked protein disulfide isomerase variants cause motor dysfunction.

Authors:  Ute Woehlbier; Alicia Colombo; Mirva J Saaranen; Viviana Pérez; Jorge Ojeda; Fernando J Bustos; Catherine I Andreu; Mauricio Torres; Vicente Valenzuela; Danilo B Medinas; Pablo Rozas; Rene L Vidal; Rodrigo Lopez-Gonzalez; Johnny Salameh; Sara Fernandez-Collemann; Natalia Muñoz; Soledad Matus; Ricardo Armisen; Alfredo Sagredo; Karina Palma; Thergiory Irrazabal; Sandra Almeida; Paloma Gonzalez-Perez; Mario Campero; Fen-Biao Gao; Pablo Henny; Brigitte van Zundert; Lloyd W Ruddock; Miguel L Concha; Juan P Henriquez; Robert H Brown; Claudio Hetz
Journal:  EMBO J       Date:  2016-02-11       Impact factor: 11.598

Review 4.  RNA-targeted Therapeutics for ALS.

Authors:  Linga V Reddy; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 5.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

6.  Neuroprotective role of the basic leucine zipper transcription factor NFIL3 in models of amyotrophic lateral sclerosis.

Authors:  So-ichi Tamai; Keisuke Imaizumi; Nobuhiro Kurabayashi; Minh Dang Nguyen; Takaya Abe; Masatoshi Inoue; Yoshitaka Fukada; Kamon Sanada
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

7.  Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Eiichi Tokuda; Shunsuke Watanabe; Eriko Okawa; Shin-ichi Ono
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 8.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

9.  Identification of rare protein disulfide isomerase gene variants in amyotrophic lateral sclerosis patients.

Authors:  Paloma Gonzalez-Perez; Ute Woehlbier; Ru-Ju Chian; Peter Sapp; Guy A Rouleau; Claire S Leblond; Hussein Daoud; Patrick A Dion; John E Landers; Claudio Hetz; Robert H Brown
Journal:  Gene       Date:  2015-04-22       Impact factor: 3.688

10.  Increased ROS Level in Spinal Cord of Wobbler Mice due to Nmnat2 Downregulation.

Authors:  Pascal Röderer; Lara Klatt; Felix John; Verena Theis; Konstanze F Winklhofer; Carsten Theiss; Veronika Matschke
Journal:  Mol Neurobiol       Date:  2018-03-16       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.